Forest Inks Alzheimer's Drug Deal – Analyst Blog
We currently have a Neutral recommendation on Forest Labs. The stock carries a Zacks #4 Rank (short-term Sell rating). Forest Labs has been under a lot of pressure following the entry of generic versions of its depression drug, Lexapro, earlier this year.
Full News here – Read more on NASDAQ